These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8776941)

  • 21. The characterisation of peptidyl prolyl cis-trans isomerase (PPI) activity associated with the endoplasmic reticulum.
    Bose S; Freedman RB
    Biochem Soc Trans; 1992 Aug; 20(3):256S. PubMed ID: 1426548
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunosuppression. Convergence of drug action.
    Freedman RB
    Nature; 1989 Oct; 341(6244):692. PubMed ID: 2477712
    [No Abstract]   [Full Text] [Related]  

  • 23. Correlation of cyclosporine and metabolite binding to cyclophilin and a 50 kDa binding protein with in vitro immunosuppression: a preliminary report.
    Donnelly JG; Russell RL; Palaszynski EW; Copeland KR; Yatscoff RW; Chan MM; Soldin SJ
    Clin Biochem; 1991 Feb; 24(1):71-4. PubMed ID: 2060135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of prolyl-peptidyl isomerase to mediate cyclosporine suppression of intracellular activation signal generation.
    Kimball PM; Kerman RH; Kahan BD
    Transplantation; 1991 Feb; 51(2):509-13. PubMed ID: 1994547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular targets of cyclosporine.
    Fairley JA
    J Am Acad Dermatol; 1990 Dec; 23(6 Pt 2):1329-32; discussion 1332-4. PubMed ID: 2277142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The X-ray structure of (MeBm2t)1-cyclosporin complexed with cyclophilin A provides an explanation for its anomalously high immunosuppressive activity.
    Mikol V; Kallen J; Walkinshaw MD
    Protein Eng; 1994 May; 7(5):597-603. PubMed ID: 8073029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purification and characterization of human T-cell cyclophilin expressed in Escherichia coli.
    Levy MA; Brandt M; Livi GP; Bergsma DJ
    Transplant Proc; 1991 Feb; 23(1 Pt 1):319-22. PubMed ID: 1990542
    [No Abstract]   [Full Text] [Related]  

  • 28. The mechanism of action of cyclosporine: a perspective for the 90's.
    Halloran PF; Madrenas J
    Clin Biochem; 1991 Feb; 24(1):3-7. PubMed ID: 1711939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toward understanding the mechanism of ciclosporin (cyclosporine) immunosuppression.
    Lorber MI
    Year Immunol; 1988; 3():291-302. PubMed ID: 3327316
    [No Abstract]   [Full Text] [Related]  

  • 30. New trends in immunosuppression for renal transplantation.
    Halloran PF
    Curr Opin Nephrol Hypertens; 1994 Nov; 3(6):575-7. PubMed ID: 7881978
    [No Abstract]   [Full Text] [Related]  

  • 31. The mechanism of ciclosporin immunosuppression.
    Lorber MI
    Year Immunol; 1989; 4():253-63. PubMed ID: 2648704
    [No Abstract]   [Full Text] [Related]  

  • 32. Structure-based design of a cyclophilin-calcineurin bridging ligand.
    Alberg DG; Schreiber SL
    Science; 1993 Oct; 262(5131):248-50. PubMed ID: 8211144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catalysis steps.
    Stein RL
    Nature; 1992 Mar; 356(6364):23-4. PubMed ID: 1538777
    [No Abstract]   [Full Text] [Related]  

  • 34. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases.
    Kay JE
    Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):361-85. PubMed ID: 8670043
    [No Abstract]   [Full Text] [Related]  

  • 35. Potential roles of other FK 506-binding proteins in mediating the effects of FK 506.
    Siekierka JJ; Wiederrecht G; Cryan J; Hung SH; Comisky M; Sigal NH
    Transplant Proc; 1991 Dec; 23(6):2720-1. PubMed ID: 1721256
    [No Abstract]   [Full Text] [Related]  

  • 36. Crystallisation and preliminary X-ray diffraction studies of cyclophilin-tetrapeptide and cyclophilin-cyclosporin complexes.
    Zurini M; Kallen J; Mikol V; Pfluegl G; Jansonius JN; Walkinshaw MD
    FEBS Lett; 1990 Dec; 276(1-2):63-6. PubMed ID: 2265714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the properties of the CsA analogs monoacetyl CyC (o-acetyl-threonine2 cyclosporin) and methyl-alanyl CsA (N-methyl-L-alanyl6 cyclosporin); monoacetyl cyclosporin is immunosuppressive without binding to cyclophilin.
    el Rouby S; Shi Y; Reem GH
    Clin Exp Immunol; 1992 Jul; 89(1):136-42. PubMed ID: 1628422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo pharmacological effects of ciclosporin and some analogues.
    Borel JF; Baumann G; Chapman I; Donatsch P; Fahr A; Mueller EA; Vigouret JM
    Adv Pharmacol; 1996; 35():115-246. PubMed ID: 8920206
    [No Abstract]   [Full Text] [Related]  

  • 39. Mechanism of enzymatic and nonenzymatic prolyl cis-trans isomerization.
    Stein RL
    Adv Protein Chem; 1993; 44():1-24. PubMed ID: 8317295
    [No Abstract]   [Full Text] [Related]  

  • 40. Isomerase and chaperone activity of prolyl isomerase in the folding of carbonic anhydrase.
    Freskgård PO; Bergenhem N; Jonsson BH; Svensson M; Carlsson U
    Science; 1992 Oct; 258(5081):466-8. PubMed ID: 1357751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.